We think this is a very exciting discovery because this may be one way that cancer cells use the increased sugar to regulate key pathways that control growth and invasion.
Philadelphia, PA (Vocus) April 17, 2010
Researchers at Drexel University College of Medicine have discovered that a certain type of sugar found naturally in the body is elevated in breast cancer cells and is critical for cancer growth and movement. When researchers reduced and normalized the levels of this sugar, they were able to slow the growth of the cancer cells and block invasion. The findings, published in the March 1 issue of Oncogene, represent a potential new therapeutic target for treating aggressive forms of breast cancer.
Scientists have known for years that cancer cells are addicted to sugar. Compared to neighboring normal cells, cancer cells take up nearly ten times more sugar. The cancer cells use the increased sugar levels to fuel rapid cell growth and spread. The Drexel researchers studied a particular sugar-based protein modification known as O-GlcNAc. Alterations in this modification have been linked previously to diabetes and Alzheimer’s disease, but not to cancer.
“This sugar, O-GlcNAc, is used inside cells to tag proteins and alter their function,” said lead author Mauricio J. Reginato, Ph.D., assistant professor in the Department of Biochemistry and Molecular Biology at Drexel University College of Medicine. “We think this is a very exciting discovery because this may be one way that cancer cells use the increased sugar to regulate key pathways that control growth and invasion.”
Reginato and his colleagues studied established cells from patients with estrogen-independent breast cancer, the most aggressive form of the disease, which does not respond well to current treatments. The researchers found that compared to normal mammary cells, all the breast cancer cells contained elevated levels of O-GlcNAc, as well as increased levels of the enzyme responsible for adding this sugar to protein.
When they reduced the levels of the O-GlcNAc enzyme, or blocked its activity with a drug, they reduced the growth of breast cancer and also blocked the invasion. In addition, by reducing the enzyme levels, they also reduced levels of a protein known as FoxM1, which is known to play a critical role in controlling cancer growth and spread.
The Drexel researchers and collaborators are now working to develop more potent chemicals to target the O-GlcNAc enzyme, a potential new therapeutic target for treating breast cancer and possibly other cancers.
“We looked at cancer databases and found that this enzyme is also elevated in other types of cancers.” said Reginato. “Our next step will be to study those cancers more closely to determine if we can achieve the same effect.”
About Drexel University College of Medicine
Drexel University College of Medicine has established some of the most highly innovative and rigorous academic programs available today, incorporating the University’s expertise in engineering and technology into traditional medical training. The College of Medicine is home to one of the nation’s leading centers for spinal cord research; one of the foremost centers for malaria study; and a highly regarded HIV/AIDS program with extensive NIH-funded research in prevention and therapeutic interventions. Drexel University College of Medicine has been designated a Vanguard National Center of Excellence in Women’s Health by the U.S. Department of Health & Human Services, and is highly respected in numerous other specialties including autism, cardiology, minimally invasive surgery, and toxicology. Visit http://www.drexelmed.edu for more information.